Heightened risk of breast cancer following pregnancy: Could lasting systemic immune alterations contribute?

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 6, 2007, Pages 1082-1086

  Shakhar, Keren ^a   Valdimarsdottir, Heiddis B ^a   Bovbjerg, Dana H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER RISK; CELLULAR IMMUNITY; CYTOTOXICITY; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; KINETICS; LABORATORY; MODEL; NATURAL KILLER CELL; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RESEARCH; REVIEW;

AGE FACTORS; BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; MODELS, IMMUNOLOGICAL; PREGNANCY; REPRODUCTIVE HISTORY; RISK FACTORS;

EID: 34250824190     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0014     Document Type: Review

References (83)

1. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
2. Polyak K. Pregnancy and breast cancer: the other side of the coin. Cancer Cell 2006;9:151-3.
3. Albrektsen G, Heuch I, Hansen S, Kvale G. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. Br J Cancer 2005;92:167-75.
4. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994;331:5-9.
5. Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC. Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control 2002;13:299-305.
6. Palmer JR, Wise LA, Horton NJ, Adams-Campbell LL, Rosenberg L. Dual effect of parity on breast cancer risk in African-American women. J Natl Cancer Inst 2003;95:478-83.
7. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. "Hormonal"" risk factors, "breast tissue age" and the age-incidence of breast cancer. Nature 1983;303:767-70.
8. Robertson C, Primic-Zakelj M, Boyle P, Hsieh CC. Effect of parity and age at delivery on breast cancer risk in Slovenian women aged 25-54 years. Int J Cancer 1997;73:1-9.
9. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 2006;8:R27.
10. Rosner B, Colditz GA. Nurses' health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 1996;88:359-64.
11. Russo J, Balogh GA, Heulings R, et al. Molecular basis of pregnancy-induced breast cancer protection. Eur J Cancer Prev 2006;15:306-42.
12. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982;2:5-73.
13. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 2006;6:281-91.
14. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-33.
15. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
16. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006;102:89-96.
17. Gupta PB, Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol 2006;102:71-8.
18. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28.
19. Phillips KA, Milne RL, Friedlander ML, et al. Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. J Clin Oncol 2004;22:699-705.
20. Markert UR, Fitzgerald JS, Seyfarth L, et al. Lessons from reproductive immunology for other fields of immunology and clinical approaches. Chem Immunol Allergy 2005;89:169-79.
21. Sargent IL, Borzychowski AM, Redman CW. NK cells and human pregnancy - an inflammatory view. Trends Immunol 2006;27:399-404.
22. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002;2:656-63.
23. Veenstra van Nieuwenhoven AL, Heineman MJ, Faas MM. The immunology of successful pregnancy. Hum Reprod Update 2003;9:347-57.
24. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993;14:353-6.
25. Trowsdale J, Betz AG. Mother's little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol 2006;7:241-6.
26. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update 2005;11:411-23.
27. Mincheva-Nilsson L, Nagaeva O, Chen T, et al. Placenta-derived soluble MHCclass I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J Immunol 2006;176:3585-92.
28. Hanna J, Goldman-Wohl D, Hamani Y, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006;12:1065-74.
29. Leonard S, Murrant C, Tayade C, van den Heuvel M, Watering R, Croy BA. Mechanisms regulating immune cell contributions to spiral artery modification - facts and hypotheses - a review. Placenta 2006;27 Suppl A:S40-6.
30. Dosiou C, Giudice LC. Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. Endocr Rev 2005;26:44-62.
31. Hahn S, Huppertz B, Holzgreve W. Fetal cells and cell free fetal nucleic acids in maternal blood: new tools to study abnormal placentation? Placenta 2005;26:515-26.
32. Barinaga M. Cells exchanged during pregnancy live on. Science 2002;296:2169-72.
33. Baley JE, Schacter BZ. Mechanisms of diminished natural killer cell activity in pregnant women and neonates. J Immunol 1985;134:3042-8.
34. Gabrilovac J, Zadjelovic J, Osmak M, Suchanek E, Zupanovic Z, Boranic M. NK cell activity and estrogen hormone levels during normal human pregnancy. Gynecol Obstet Invest 1988;25:165-72.
35. Gregory CD, Shah LP, Lee H, Scott IV, Golding PR. Cytotoxic reactivity of human natural killer (NK) cells during normal pregnancy: a longitudinal study. J Clin Lab Immunol 1985;18:175-81.
36. Okamura K, Furukawa K, Nakakuki M, Yamada K, Suzuki M. Natural killer cell activity during pregnancy. Am J Obstet Gynecol 1984;149:396-9.
37. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004;5:266-71.
38. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 2004;112:38-43.
39. Eblen AC, Gercel-Taylor C, Shields LB, Sanfilippo JS, Nakajima ST, Taylor DD. Alterations in humoral immune responses associated with recurrent pregnancy loss. Fertil Steril 2000;73:305-13.
40. Zenclussen AC, Gentile T, Kortebani G, Mazzolli A, Margni R. Asymmetric antibodies and pregnancy. Am J Reprod Immunol 2001;45:289-94.
41. Croce MV, Isla-Larrain MT, Capafons A, Price MR, Segal-Eiras A. Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 2001;69:1-11.
42. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000;18:574-83.
43. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998;339:285-91.
44. Gordon C. Pregnancy and autoimmune diseases. Best Pract Res Clin Rheumatol 2004;18:359-79.
45. Lindsay L, Jackson LA, Savitz DA, et al. Community influenza activity and risk of acute influenza-like illness episodes among healthy unvaccinated pregnant and postpartum women. Am J Epidemiol 2006;163:838-48.
46. Diagne N, Rogier C, Cisse B, Trape JF. Incidence of clinical malaria in pregnant women exposed to intense perennial transmission. Trans R Soc Trop Med Hyg 1997;91:166-70.
47. Kumar RM, Uduman SA, Khurrana AK. Impact of pregnancy on maternal AIDS. J Reprod Med 1997;42:429-34.
48. Shakhar K, Ben-Eliyahu S, Loewenthal R, Rosenne E, Carp H. Differences in number and activity of peripheral natural killer cells in primary versus secondary recurrent miscarriage. Fertil Steril 2003;80:368-75.
49. Callaghan WM, Berg CJ. Pregnancy-related mortality among women aged 35 years and older, United States, 1991-1997. Obstet Gynecol 2003;102:1015-21.
50. Laibl VR, Sheffield JS. Influenza and pneumonia in pregnancy. Clin Perinatol 2005;32:727-38.
51. Valdimarsdottir HB, Zakowski SG, Gerin W, Mamakos J, Pickering T, Bovbjerg DH. Heightened psychobiological reactivity to laboratory stressors in healthy women at familial risk for breast cancer. J Behav Med 2002;25:51-65.
52. Huang H, Patel DD, Manton KG. The immune system in aging: roles of cytokines, T cells and NK cells. Front Biosci 2005;10:192-215.
53. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-7.
54. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol 2006;16:80-8.
55. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001;84:1188-92.
56. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
57. Black MM, Zachrau RE, Ashikari RH, Hankey BF. Prognostic significance of cellular immunity to autologous breast carcinoma and glycoprotein 55. Arch Surg 1989;124:202-6.
58. Cannon GB, Pomerantz R. Cell-mediated immune responses-prognostic indicators of survival from breast cancer. Int J Cancer 1989;44:995-9.
59. McCoy JL, Rucker R, Petros JA. Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res Treat 2000;60:227-34.
60. Adler A, Stein JA, Ben-Efraim S. Immunocompetence, immunosuppression, and human breast cancer. III. Prognostic significance of initial level of immunocompetence in early and advanced disease. Cancer 1980;45:2074-83.
61. Burford-Mason A, Gyte GM, Watkins SM. Phytohaemagglutinin responsiveness of peripheral lymphocytes and survival in patients with primary breast cancer. Breast Cancer Res Treat 1989;13:243-50.
62. Mandeville R, Lamoureux G, Legault-Poisson S, Poisson R. Biological markers and breast cancer. A multiparametric study. II. Depressed immune competence. Cancer 1982;50:1280-8.
63. Hefler LA, Grimm C, Lantzsch T, et al. Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res 2005;11:5718-21.
64. Langsenlehner U, Krippl P, Renner W, et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 2005;90:113-5.
65. Mestiri S, Bouaouina N, Ahmed SB, et al. Genetic variation in the tumor necrosis factor-a promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 2001;91:672-8.
66. Bovbjerg DH, Valdimarsdottir H. Familial cancer, emotional distress, and low natural cytotoxic activity in healthy women. Ann Oncol 1993;4:745-52.
67. Shevde LA, Joshi NN, Shinde SR, Nadkarni JJ. Studies on functional status of circulating lymphocytes in unaffected members from cancer families. Hum Immunol 1998;59:373-81.
68. Strayer DR, Carter WA, Brodsky I. Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity. Breast Cancer Res Treat 1986;7:187-92.
69. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80:S254-64.
70. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905-13.
71. Oruc MT, Soran A, Jain AK, Wilson JW, Fung J. De novo breast cancer in patients with liver transplantation: University of Pittsburgh's experience and review of the literature. Liver Transpl 2004;10:1-6.
72. Cabrera T, Angustias Fernandez M, Sierra A, et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996;50:127-34.
73. Gudmundsdottir I, Gunnlaugur Jonasson J, Sigurdsson H, Olafsdottir K, Tryggvadottir L, Ogmundsdottir HM. Altered expression of HLA class I antigens in breast cancer: association with prognosis. Int J Cancer 2000;89:500-5.
74. Clayton A, Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 2005;34:206-13.
75. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
76. Botelho F, Clark DA. How might pregnancy immunize against breast cancer? Am J Reprod Immunol 1998;39:279-83.
77. Janerich DT. The influence of pregnancy on breast cancer risk: is it endocrinological or immunological? Med Hypotheses 1980;6:1149-55.
78. Mohle-Boetani J, Grosser S, Malec M, Whittemore AS. Survival advantage among patients with breast cancer diagnosed at 45 to 49 years of age. N Engl J Med 1986;315:587.
79. Oliver RT. Pregnancy and breast cancer. Lancet 1994;344:471-2.
80. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
81. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10:15-8.
82. Wilczynski JR. Cancer and pregnancy share similar mechanisms of immunological escape. Chemotherapy 2006;52:107-10.
83. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg 2003;138:91-8; discussion 99.